Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Common Stock Issued

Cash raised by issuing new shares.

Cardiff Oncology, Inc.NASDAQ: CRDF

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued growth accelerates

Q1 FY2026 common stock issued of $105K rose 3400.0% year over year, ahead of the -95.0% change in trailing-twelve-month common stock issued. Sequentially, it fell 95.9% from the prior quarter. Over 3 fiscal years it compounded at +225.3% a year.

Context

  • Common stock issued amounted to 435.2% of revenue in FY2025, down 7384.2 pp from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +3400.0% holds above the trailing-twelve-month pace of -95.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$105K-95.9% QoQ
Last fiscal yearDec 2025
$2.58M-95.2% YoY
LTMMar 2026
$2.66M-95.0% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3400.0%——
1 year-95.2%——
3-year CAGR+225.3%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
2.58M USD
Year-over-year change
-95.2%
4-year CAGR
-47.6%

Common Stock Issued vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -95.0% is the lowest of 9, against a peer median of +164.6%.
  • Common stock issued amounts to 506.3% of revenue for CRDF, versus a peer median of 1837.6%.
CRDF Competitors
Common Stock Issued for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PEPGPepGen Inc.LTM Mar 2026$109.49M USD+6044.2%-1.8%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$104.89M USD+75017.8%+219.2%5879.2%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$77.35M USD+115.3%——
FBRXForte Biosciences, Inc.LTM Mar 2026$71.8M USD+41.6%+119.9%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$58.23M USD+213.9%+477.6%1837.6%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$14.61M USD+34.0%+589.1%—
IPHAInnate Pharma S.A.FY2025€14.39M EUR+391.5%+317.3%516.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.66M USD-95.0%+225.3%506.3%
MOLNMolecular Partners AGLTM Mar 2026CHF 73.01K CHF+82.5%-36.8%—
Peer median (excluding CRDF) —+164.6%+219.2%1837.6%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.